J&J's carisbamate shows mixed efficacy in epilepsy in Phase III
This article was originally published in Scrip
Executive Summary
Johnson & Johnson's anti-epileptic candidate, carisbamate, has shown mixed efficacy as an adjunctive treatment of partial onset seizures in Phase III data that were presented at the recent American Epilepsy Society meeting.